More than 30 years of experience in global drug development, gene/cell therapy medicines, biological drugs, and rare diseases at different biotech/biopharma companies, including Shanghai Henlius Biotech, Spark Therapeutics (acquired by Roche), Biogen, Bayer HealthCare, and others of progressive responsibilities.

Proven track record of 250+ cumulative sum of IND, NDA/BLA, and MAA submissions in North/South Americas, Europe, India, South Africa, Brazil, Argentina (ISBA) and APAC, leading to the participation in the development of 21 approved products from clinical development to marketing approval and launch.

Has been published more than 100 book chapters and scientific papers in highly-regarded peer-reviewed journals, including New England Journal of Medicine, Nature Medicine, Nature, Cell, Science, and Blood.

Holds an M.B.A. from Harvard Business School, received Ph.D. in Neuroscience and certified in clinical research from the University of California-San Francisco Medical School.

Fully responsible for the company's strategic layout, team building, project management and system construction as well as leading the Strategic Portfolio & Project management (SPPM), R&D management, and drug development of multiple gene replacement and gene editing drugs.

Championed and completed four rounds of financial fundraising and reorganization of the company and completed numbers of external technology platforms and research collaborations.

Prior to founding HuidaGene, Xuan served as Associate Principal Investigator at the Institute of Neuroscience of the Chinese Academy of Sciences with 10 years of experience in optimizing novel gene editing technologies, establishing animal disease models, and developing gene therapy drugs, leading to publications in international academic journals, such as Cell Research, Developmental Cell, etc., with the first or corresponding author. He has applied several international invention patents and won the “Special Talent Grant of Shanghai Qiming Plan”.

Holds an Ph.D. in Neurobiology at Institute of Neuroscience of the Chinese Academy of Sciences and a B.S. in Biology from Harbin Institute of Technology.

More than 10 years of preclinical development and translational science experience in animal disease modeling development and validation, gene editing tool optimization, viral vector engineering & design, and production process development. 

Successfully led more than 10 drug discovery programs, 6 preclinical pipelines, and 20+ AAV capsid screening programs and received awards such as “Outstanding Innovation and Entrepreneurial Talent” in Zhangjiang National Innovation Demonstration Zone.

Prior to founding HuidaGene, Linyu served as Head of Animal Facility at Shanghai Institute of Organic Chemistry (SIOC) and Head of Gene Editing Facility at the Center for Excellence in Brain Science and Intelligence Technology (CEBSIT) of the Chinese Academy of Sciences (CAS)

Holds an Ph.D. in Developmental Biology from Shanghai Institute of Biochemistry of the Chinese Academy of Sciences and a B.S. in Biotechnology from Nanjing University.

Over 15 years of experience in accounting, auditing, and investment banking, corporate financing, IPO, general financing, investor relation, tax planning, and M&A in China, US Top 4 public accounting firms and pharmaceutical companies. 

With deep involvement in pharmaceutical and capital market industries, Alex was VP of Finance and Secretary of the Board of Directors at Tasly Biopharma focusing on Corporate Finance, IPO project, Internal Control and Compliance, Corporate Governance, Investor Relationship and Public Relationship prior to joining HuidaGene.     

Has served in several domestic and multinational companies such as General Electric, KPMG International, PricewaterhouseCoopers US, PingAn Securities Investment and Tenry Pharm.  Holds an E.M.B.A. in Finance from Shanghai Advanced Institute of Finance (SAIF) at Shanghai Jiao Tong University and obtained dual B.B.A. degrees in Marketing and Accounting from the Shanghai University of Finance and Economics.

More than 20 years of experience in human resources, organizational development & effectiveness, leadership and people development, employee relations, and change management in pharmaceutical industry.

Prior to joining HuidaGene, Femi was Chief Human Resources Officer (CHO) at Tasly Pharma, principal HRBP for Roche China R&D, Oncology BU and Roche Australia, and held various positions at Roche, Nokia, Sobey Digital Technology, and TCL Technology.

Extensive knowledge in organization and people insights across industries of Pharmaceuticals, Communications, IT and FMCG in both domestic and overseas and rich experiences in designing and developing the organization from 0 to 1 with solid track record in leadership and talent development practices.

Holds an M.B.A. from Sichuan University and a B.E. in Mechanical and Electrical Engineering from University of Electronic Science and Technology.

More than 18 years of biopharmaceutical industry experiences in process development, process characterization, process scaling up, process validation, product release & control, and tech transfer.

Rich knowledge in biologic process/technical development, CMC/CDMO management, project management, cGMP manufacturing and regulatory regulations and requirements for biologics and IND/NDA/BLA submission with successful commercialization of 5 products.

Prior to joining HuidaGene, she was Deputy General Manager of Upstream Process Development at Shanghai Henlius Biotech for 11+ years.    

Holds a M.S. in Histoembryology from Tongji University and a B.S. in Medicine from Southeast University .

Over 10 years of research and industry experiences with deep knowledge in company creation, strategic alliances management, and technology licensing. 

Deep engagement in the venture capital investment for gene therapy and cell therapy companies including Citryll BV, Acrigen Biosciences, and DNAlite Therapeutics.

Prior to joining HuidaGene, Xixi was VP of Business Development at DNALite Therapeutics and analyst positions at several capital partner organizations.

Holds M.Phil (MS) degree in Genetics and MPhil in Bioscience Enterprise (M.B.E) from the University of Cambridge with research experience in Bioengineering and Genetics from Imperial College London and University of Cambridge.  

Nearly 10 years’ experiences in business development, alliance management, and fund-raising in biotech/pharmaceutical industry, with track records in completing multiple types of transactions and rounds of fundraising.

Extensive knowledge in cutting-edge trends and biopharmaceutical industry landscape, with excellent coordination and communication across multi-functional teams.

Prior to joining HuidaGene, she severed as Director of Corporate Development at IMPACT Therapeutics, Senior Manager of Business Development and Project Management at Frontier Biotech, and Business Development Manager at Shenogen Pharma.

Holds M.S. and B.S. in Biochemistry and Molecular Biology from Peking University.

Over 10 years experience in legal, patent, quality management and registration affairs in medicinal, biological, and chemical fields.

Solid patent expertise focusing on various advanced medical and biological techniques including, e.g., CRISPR/Cas, CAR-T therapy, RNA interference,    

Prior to HuidaGene, served as an IP lawyer at King & Wood Mallesons for about 7 years. Providing extensive legal services including patent drafting, prosecution, search, reexamination, validity and infringement analysis, invalidation, administrative and civil infringement litigation, pre-IPO IP due diligence for established domestic and international entities, such as Alnylam, Novartis, Chinese Academy of Sciences, Tsinghua University, WuXi AppTec, Novozymes, Novo Nordisk, and Roche.   

Qualified PRC attorney and patent attorney, holds a M.S. in Chemical and Biological Sciences from Chalmers University of Technology in Gothenburg and a B.S. in Pharmacy from China Pharmaceutical University.